LONSURF
Colorectal Cancer
CommercialMarketed
Key Facts
About Otsuka Holdings
Otsuka Holdings Co., Ltd. is a multinational pharmaceutical and healthcare company founded in 1964, headquartered in Tokyo, Japan. The company has built a strong reputation in central nervous system disorders, with major commercial successes including the antipsychotic Abilify and depression treatment Rexulti. Otsuka operates globally with a focus on innovation in psychiatry, neurology, oncology, and nephrology, maintaining a robust pipeline of novel therapeutics and a commitment to addressing unmet medical needs.
View full company profileTherapeutic Areas
Other Colorectal Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CY-101 + Pembrolizumab | Cytovation | Phase 1/2 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| Botensilimab + Balstilimab | Agenus | Phase 2 |
| Undisclosed Degrader (ABM Program) | Captor Therapeutics | Preclinical |